(Circulation. 1995;92:1604-1611.)
© 1995 American Heart Association, Inc.
Articles |
Therapy With Immunoglobulin Suppresses Myocarditis in a Murine Coxsackievirus B3 Model
Antiviral and Anti-inflammatory Effects
Presented in part at the 66th Scientific Sessions of the American Heart Association, Atlanta, Ga, November 11-14, 1993.
From the The Second Department of Internal Medicine, Faculty of Medicine, Toyama Medical and Pharmaceutical University, Toyama, Japan.
Correspondence to Chiharu Kishimoto, MD, PhD, The Second Department of Internal Medicine, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama 930-01, Japan.
Background The treatment of some inflammatory diseases (eg, Kawasaki disease) with immunoglobulin has been demonstrated to be effective. Accordingly, to elucidate the mechanism underlying such actions of immunoglobulin, we examined its effects on murine coxsackievirus B3 (CB3) myocarditis.
Methods and Results An in vitro study showed dose-dependent suppression of CB3 by immunoglobulin. Immunoglobulin 1 g · kg-1 · d-1 IP was administered to CB3-infected C3H/He mice daily for 2 weeks, beginning simultaneously with virus inoculation in experiment 1 and on day 14 after virus inoculation in experiment 2. In both experiments, survival was higher in treated than in control mice; at the time of death, inflammatory cell infiltration and the severity of necrosis and calcification also were reduced. Notably, in experiment 1, immunoglobulin administration completely suppressed the development of myocarditis. Serum-neutralizing antibody titers in the treated mice were significantly higher than those in untreated mice in experiment 1 but not in experiment 2. The circulating antibodies of the treated mice were primarily of exogenous origin in experiment 1 and of exogenous and endogenous origins in experiment 2. The analysis of splenic lymphocyte subsets revealed a marked decrease of the B cell population in the treated mice.
Conclusions Immunoglobulin therapy completely suppressed acute CB3 myocarditis by transferring the neutralizing antibody into the host in the acute viremic stage and induced an anti-inflammatory effect in the subsequent aviremic stage; the reduction of the splenic B-cell population may be closely associated with an anti-inflammatory effect.
Key Words: myocarditis • immune system • viruses
This article has been cited by other articles:
 |
|
 |
|
  L. T. Cooper, R. Virmani, N. M. Chapman, A. Frustaci, R. J. Rodeheffer, M. W. Cunningham, and D. M. McNamara National Institutes of Health-Sponsored Workshop on Inflammation and Immunity in Dilated Cardiomyopathy Mayo Clin. Proc., February 1, 2006; 81(2): 199 - 204. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Shioji, Z. Yuan, T. Kita, and C. Kishimoto Immunoglobulin treatment suppressed adoptively transferred autoimmune myocarditis in severe combined immunodeficient mice Am J Physiol Heart Circ Physiol, December 1, 2004; 287(6): H2619 - H2625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Yuan, C. Kishimoto, H. Sano, K. Shioji, Y. Xu, and M. Yokode Immunoglobulin treatment suppresses atherosclerosis in apolipoprotein E-deficient mice via the Fc portion Am J Physiol Heart Circ Physiol, July 11, 2003; 285(2): H899 - H906. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Klingel, J.-J. Schnorr, M. Sauter, G. Szalay, and R. Kandolf {beta}2-Microglobulin-Associated Regulation of Interferon-{gamma} and Virus-Specific Immunoglobulin G Confer Resistance Against the Development of Chronic Coxsackievirus Myocarditis Am. J. Pathol., May 1, 2003; 162(5): 1709 - 1720. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Kishimoto, H. Takada, H. Kawamata, M. Umatake, and H. Ochiai Immunoglobulin Treatment Prevents Congestive Heart Failure in Murine Encephalomyocarditis Viral Myocarditis Associated with Reduction of Inflammatory Cytokines J. Pharmacol. Exp. Ther., November 1, 2001; 299(2): 645 - 651. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. McNamara, R. Holubkov, R. C. Starling, G. W. Dec, E. Loh, G. Torre-Amione, A. Gass, K. Janosko, T. Tokarczyk, P. Kessler, et al. Controlled Trial of Intravenous Immune Globulin in Recent-Onset Dilated Cardiomyopathy Circulation, May 8, 2001; 103(18): 2254 - 2259. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Kishimoto, N. Takamatsu, H. Kawamata, H. Shinohara, and H. Ochiai Immunoglobulin treatment ameliorates murine myocarditis associated with reduction of neurohumoral activity and improvement of extracellular matrix change J. Am. Coll. Cardiol., November 15, 2000; 36(6): 1979 - 1984. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Kawai From Myocarditis to Cardiomyopathy: Mechanisms of Inflammation and Cell Death : Learning From the Past for the Future Circulation, March 2, 1999; 99(8): 1091 - 1100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Kishimoto, H. Takada, Y. Hiraoka, D. M. McNamara, and A. M. Feldman Intravenous IgG: Supertherapy for Myocarditis and Acute Dilated Cardiomyopathy • Response Circulation, February 23, 1999; 99(7): 975 - 978. [Full Text] [PDF]
|
|
|
|
|
|
D. M. McNamara, W. D. Rosenblum, K. M. Janosko, M. K. Trost, F. S. Villaneuva, A.J. Demetris, S. Murali, and A. M. Feldman Intravenous Immune Globulin in the Therapy of Myocarditis and Acute Cardiomyopathy Circulation, June 3, 1997; 95(11): 2476 - 2478. [Abstract] [Full Text]
|
|
|
|
 |
|
 K. Shioji, C. Kishimoto, and S. Sasayama Fc Receptor-Mediated Inhibitory Effect of Immunoglobulin Therapy on Autoimmune Giant Cell Myocarditis: Concomitant Suppression of the Expression of Dendritic Cells Circ. Res., September 14, 2001; 89(6): 540 - 546. [Abstract] [Full Text] [PDF]
|
|